6 terminated, 3 completed. 8 Phase 2, 7 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 8 | Terminated 5, Completed 3 |
| Phase 1 | 7 | Terminated 5, Completed 2 |
Follow Aegera Therapeutics: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| AEG35156 in Combination With High-dose Cytarabine and Idarubicin in AML Following Failure of a Single Standard Dose Cytarabine Based Frontline Induction Regimen AEG35156 - Leukemia | Phase 2 | Terminated | Aegera Therapeutics | 60 | 2009-11-01 | 2011-07-13 |
| XIAP Antisense AEG35156 in Combination With Sorafenib in Patients With Advanced Hepatocellular Carcinoma (HCC) AEG35156 antisense IV infusion, Sorafenib - Advanced Hepatocellular Carcinoma | Phase 1 / Phase 2 | Completed | Aegera Therapeutics | 75 | 2009-03-01 | 2011-07-13 |
| Safety and Efficacy of AEG33773 Versus Placebo in Patients With Painful Diabetic Peripheral Neuropathy AEG33773 oral dosing - Diabetic Peripheral Neuropathy, Chronic Pain | Phase 2 | Completed | Aegera Therapeutics | 128 | 2009-03-01 | 2010-05-31 |
| A Phase 1-2, Multicenter, Open-Label Study of AEG35156 in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia and Indolent B-Cell Lymphomas AEG35156 antisense IV infusion - Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell | Phase 1 / Phase 2 | Terminated | Aegera Therapeutics | 25 | 2008-09-01 | 2011-07-13 |
| A Phase 1-2, XIAP Antisense AEG35156 With Weekly Paclitaxel in Patients With Advanced Breast Cancer AEG35156 - Human Mammary Carcinoma | Phase 1 / Phase 2 | Terminated | Aegera Therapeutics | 61 | 2007-11-01 | 2009-12-02 |
| A Phase 1-2 XIAP Antisense AEG35156 With Carboplatin and Paclitaxel in Patients With Advanced Non-Small Cell Lung Cancer AEG35156 - Carcinoma, Non-Small-Cell Lung | Phase 1 / Phase 2 | Terminated | Aegera Therapeutics | 54 | 2007-09-01 | 2009-07-30 |
| A Phase 1-2, XIAP Antisense AEG35156 With Gemcitabine in Patients With Advanced Pancreatic Cancer AEG35156 - Carcinoma, Pancreas | Phase 1 / Phase 2 | Terminated | Aegera Therapeutics | 48 | 2007-09-01 | 2009-12-01 |
| Study of XIAP Antisense for Advanced Cancers AEG35156 - Advanced Cancer | Phase 1 | Terminated | Aegera Therapeutics | 30 | 2006-06-01 | 2008-08-21 |
| Study of XIAP Antisense Given With Chemotherapy for Refractory/Relapsed AML XIAP antisense - Leukemia, Myelomonocytic, Acute | Phase 1 / Phase 2 | Completed | Aegera Therapeutics | 54 | 2005-10-01 | 2009-12-01 |
Leukemia (3) · Neoplasms (2) · Breast Neoplasms (1) · Carcinoma (1) · Carcinoma, Non-Small-Cell Lung (1) · Chronic Pain (1) · Hyperalgesia (1) · Leukemia, Lymphocytic, Chronic, B-Cell (1) · Leukemia, Myelomonocytic, Acute (1) · Leukemia, Promyelocytic, Acute (1) · Lymphoma (1) · Lymphoma, B-Cell (1) · Pain (1) · Recurrence (1)
United States (7) · Canada (4) · Bulgaria (1) · China (1) · Germany (1) · Romania (1) · United Kingdom (1)
Jacques Jolivet, MD, FACP (3) · Jacques Jolivet, MD (2) · Aaron Schimmer, MD (1) · Ann Shing Lee, MBChB(CUHK), FHKAM(Rad) (1) · Daniel D Von Hoff, MD, FACP (1) · David M Loesch, MD (1) · Jacques Jolivet, MD, FRCP(C) (1) · John Sweetenham, MD (1) · Robert M Jotte, MD (1)
2009 (1)